540788 ASPIRA

Aspira Pathlab & Diagnostics Share Price

 

 

Start SIP in ASPIRA

Start SIP

Performance

  • Low
  • ₹63
  • High
  • ₹64
  • 52 Week Low
  • ₹50
  • 52 Week High
  • ₹107
  • Open Price₹64
  • Previous Close₹63
  • Volume334

Investment Returns

  • Over 1 Month -2.48%
  • Over 3 Month + 3.14%
  • Over 6 Month + 12.3%
  • Over 1 Year + 2.94%

Smart Investing Starts Here Start SIP with Aspira Pathlab & Diagnostics for Steady Growth!

Invest Now

Aspira Pathlab & Diagnostics Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 19
  • PEG Ratio
  • 0
  • Market Cap Cr
  • 65
  • P/B Ratio
  • 4.5
  • Average True Range
  • 3.93
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • 0.31
  • RSI
  • 44.41
  • MFI
  • 16.79

Aspira Pathlab & Diagnostics Financials

Aspira Pathlab & Diagnostics Technicals

EMA & SMA

Current Price
₹63.00
+ 0.45 (0.72%)
pointer
  • Bearish Moving Average 14
  • Bullish Moving Average 2
  • 20 Day
  • ₹65.28
  • 50 Day
  • ₹64.84
  • 100 Day
  • ₹64.05
  • 200 Day
  • ₹62.55

Resistance and Support

63.49 Pivot Speed
  • R3 65.43
  • R2 64.95
  • R1 63.97
  • S1 62.51
  • S2 62.03
  • S3 61.05

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Aspira Pathlab & Diag has an operating revenue of Rs. 24.52 Cr. on a trailing 12-month basis. An annual revenue growth of 64% is outstanding, Pre-tax margin of 9% is okay, ROE of 27% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. It has recently broken out of a base in its weekly chart but failed to keep its momentum and is trading around -11% from the pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 72 which is a FAIR score but needs to improve its earnings, a RS Rating of 44 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D which indicates heavy supply, Group Rank of 33 indicates it belongs to a strong industry group of Medical-Services and a Master Score of C is fair but needs to improve. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Aspira Pathlab & Diagnostics Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-12 Quarterly Results
2025-08-12 Quarterly Results
2025-05-16 Audited Results
2025-02-07 Quarterly Results
2024-11-12 Quarterly Results

Aspira Pathlab & Diagnostics F&O

Aspira Pathlab & Diagnostics Shareholding Pattern

18.39%
60.16%
21.45%

About Aspira Pathlab & Diagnostics

  • NSE Symbol
  • ASPIRA
  • BSE Symbol
  • 540788
  • Managing Director & CEO
  • Dr. Pankaj J Shah
  • ISIN
  • INE500C01017

Similar Stocks to Aspira Pathlab & Diagnostics

Aspira Pathlab & Diagnostics FAQs

Aspira Pathlab & Diagnostics share price is ₹63 As on 25 December, 2025 | 11:13

The Market Cap of Aspira Pathlab & Diagnostics is ₹64.8 Cr As on 25 December, 2025 | 11:13

The P/E ratio of Aspira Pathlab & Diagnostics is 19 As on 25 December, 2025 | 11:13

The PB ratio of Aspira Pathlab & Diagnostics is 4.5 As on 25 December, 2025 | 11:13

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23